title: Seminal vesicle invasion: what is the best adjuvant treatment after radical prostatectomy?
abstract: OBJECTIVE
  • To evaluate the biochemical-failure free survival according to different adjuvant treatments in patients who underwent radical prostatectomy (RP) with seminal vesicle invasion (SVI).
  
  
  METHODS
  • Between 1994 and 2008, 4090 men underwent RP in nine centres. Of these, 310 men had a SVI. • Exclusion criteria were: detectable postoperative prostate-specific antigen, lymph node metastases and follow-up <18 months. • Therefore, the study group included 199 patients. Of these, 41 received adjuvant radiotherapy (RT) only, 26 received adjuvant androgen deprivation therapy (ADT) only, 50 received adjuvant ADT combined with RT and 82 were monitored. The endpoint for this analysis was biochemical no evidence of disease (bNED). • Preoperative prostate-specific antigen level, specimen Gleason score, age, clinical stage, surgical margin status and adjuvant treatment were evaluated in a multivariable analysis with respect to bNED survival.
  
  
  RESULTS
  • After a mean (range) follow-up of 60.3 (18-185) months, 88 (44.2%) patients had a biochemical relapse. • The estimated 5- and 7-year bNED survival were 32.6% and 25.9% for the observation group, 44.4% and 28.6% for the RT only group, 48.4% and 32.3% for the ADT only group and 82.8% and 62.1% for the adjuvant ADT combined with RT group. • On multivariate analysis, only adjuvant ADT combined with RT (P < 0.001) was an independent prognostic factor of biochemical relapse.
  
  
  CONCLUSIONS
  • RP appeared to be insufficient as a single treatment for patients with SVI. • The findings of the present study suggest that adjuvant ADT combined with RT after RP for patients with SVI confers a substantial benefit on 5-year bNED survival.
authors.affiliation: Department of Urology, Hôpital Nord, Chemin des Bourrely, 13915 Marseille, Cedex 20, France. cyrille.bastide@ap-hm.fr
authors.forename: Cyrille
authors.initials: C
authors.lastname: Bastide
authors.forename: Dominique
authors.initials: D
authors.lastname: Rossi
authors.forename: Eric
authors.initials: E
authors.lastname: Lechevallier
authors.forename: Franck
authors.initials: F
authors.lastname: Bladou
authors.forename: David
authors.initials: D
authors.lastname: Barriol
authors.forename: Denis
authors.initials: D
authors.lastname: Bretheau
authors.forename: Vincent
authors.initials: V
authors.lastname: Grisoni
authors.forename: Julien
authors.initials: J
authors.lastname: Mancini
authors.forename: Sophie
authors.initials: S
authors.lastname: Giusiano
authors.forename: Christophe
authors.initials: C
authors.lastname: Eghazarian
authors.forename: Antoine
authors.initials: A
authors.lastname: Van Hove
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D059186:Chemoradiotherapy, Adjuvant; D018450:Disease Progression; D018572:Disease-Free Survival; D005834:Genital Neoplasms, Male / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000209:etiology; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D012669:Seminal Vesicles / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen